Article · Safety

Peptides in South Africa: Authorities Target Unregistered Retatrutide

South African health authorities and pharmaceutical leaders have called for urgent law enforcement action against the open sale of unregistered weight loss peptides, specifically targeting retatrutide. Speaking at an industry panel in Sandton, representatives from SAHPRA, the Border Management Authority, and the Pharmaceutical Task Group warned that informal online sales and illegal compounding put public safety at risk while global reports link bootleg retatrutide to severe health hazards.

South African Authorities Call for Arrests and Seizures

At a Pharmaceutical Task Group media roundtable in Sandton, industry chairperson Dr Stavros Nicolaou called on law enforcement to seize illicit stock and prosecute sellers of unapproved peptides. BusinessTech reported on 31 October 2026 that products marketed as retatrutide are being sold illicitly across South Africa through social media platforms, wellness clinics, gyms, and informal online sellers.

SAHPRA regulatory compliance manager Daphney Fafudi stated that SAHPRA has received approximately 600 complaints during the current financial year regarding informal, illegitimate, and fake medicines. Mail & Guardian reported on 16 October 2026 that SAHPRA is opening criminal cases and coordinating with the National Prosecuting Authority to pursue illegal distributors.

Border Management Authority commissioner Michael Masiapato revealed that border officials have intercepted over 1.7 million suspicious pharmaceutical-related items. Some unregistered shipments entered the country under false customs declarations, including being mislabelled as cosmetics or carried in personal luggage.

Court Victory and Action on Compounded Products

Regulators are also tightening scrutiny on local compounding pharmacies. Mail & Guardian reported on 22 October 2026 that the Gauteng High Court issued an order in June 2026 against iDexis, a compounding pharmacy in Tshwane. The order required the business to stop manufacturing unapproved copycat weight-loss injections containing semaglutide after large quantities of compounded jabs were confiscated on site.

Industry leaders warned that unless regulatory guidelines are enforced rapidly, informal compounding and illegal peptide distribution could undermine public confidence in South Africa's medicines regulatory framework.

International Safety Warnings and Testing Concerns

Retatrutide remains an investigational molecule developed by Eli Lilly under the code LY3437943. It targets three distinct metabolic receptors: GIP, GLP-1, and glucagon. It has not been approved by SAHPRA or any medical regulator worldwide. MedicalBrief reported on 21 October 2026 that Eli Lilly plans to submit its first regulatory application to the US Food and Drug Administration in the first quarter of next year.

Safety concerns around bootleg versions of the peptide have escalated internationally. MedicalBrief reported on 21 October 2026 that the US FDA logged two patient deaths linked to unregulated retatrutide purchased from online peptide vendors, including a cardiac arrest in July 2026 and a case involving severe dehydration and malnutrition in September 2026.

Independent laboratory testing conducted for CBS News on 21 October 2026 revealed that unregulated retatrutide samples purchased online and over the counter contained non-peptide filler compounds such as phenylacetic acid, as well as bacterial contamination with 13 bacterial colonies detected in a single vial.

Clinical Findings vs Unregulated Peptides

Legitimate clinical trials demonstrate significant weight loss efficacy for retatrutide under strict medical monitoring, contrasting sharply with the risks of black-market products.

Trial / Source Publication Date Key Findings Regulatory Status
NEJM Phase 2 Trial 10 August 2023 Mean weight loss of 24.2% at 48 weeks with 12 mg dose Investigational only
Lancet TRIUMPH-2 Phase 3 10 October 2026 Mean weight loss of 18.8% at 80 weeks with 12 mg dose in type 2 diabetes Investigational only
CBS Independent Lab Test 21 October 2026 Contamination with 13 bacterial colonies and non-peptide fillers Unregulated black market

Health officials strongly advise South African consumers against purchasing unapproved retatrutide or compounded peptide injections from unauthorized sources, emphasizing that true pharmaceutical safety requires validated manufacturing standards and official SAHPRA registration.

Further reading: Crackdown on illegal weight loss drugs (mg.co.za).

See also: Is retatrutide legal in South Africa?

Frequently asked questions

What is retatrutide?

Retatrutide is an investigational triple-hormone-receptor agonist molecule developed by Eli Lilly under the code LY3437943 that targets GIP, GLP-1, and glucagon receptors.

Is retatrutide approved for use in South Africa?

No, retatrutide has not been approved by SAHPRA or any medical regulator worldwide and remains strictly investigational.

How are unregistered peptides being sold in South Africa?

Products marketed as retatrutide are sold illicitly across the country through social media platforms, wellness clinics, gyms, and informal online sellers.

What actions are South African authorities taking against illegal weight loss drugs?

Health authorities, the Border Management Authority, and the Pharmaceutical Task Group are calling for arrests, prosecutions, and the seizure of illicit stock, with SAHPRA opening criminal cases.

What safety risks are associated with black-market retatrutide?

Global reports and international testing have linked unregulated peptide products to severe health hazards, including patient deaths, severe dehydration, malnutrition, and bacterial contamination.

What do clinical trials show about retatrutide efficacy?

Legitimate clinical trials demonstrate significant weight loss efficacy under strict medical monitoring, such as a mean weight loss of 24.2% at 48 weeks in a Phase 2 trial.

Sources

  1. mg.co.za, "Crackdown on illegal weight loss drugs", 2026-10-16, https://mg.co.za/news/health/2026-10-15-crackdown-on-illegal-weight-loss-drugs
  2. mg.co.za, "Black market weight-loss drug sellers are moving fast. SA’s regulators are struggling to keep up", 2026-10-22, https://mg.co.za/news/health/2026-10-22-black-market-weight-loss-drug-sellers-are-moving-fast-sa-s-regulators-are-struggling-to-keep-up
  3. medicalbrief.co.za, "SA call for action against illegal obesity medicines suspected in US deaths", 2026-10-21, https://www.medicalbrief.co.za/sa-call-for-action-against-illegal-obesity-medicines-suspected-in-us-deaths
  4. businesstech.co.za, "Warning to people selling illegal medications", 2026-10-31, https://businesstech.co.za/news/government/880181/warning-to-people-selling-illegal-medications